In December a five-member IPEC America’s team met with the FDA to discuss the IID – which lists inactive ingredients in approved drug products – the minutes of which were published late last month.
One of the major developments stemming from the meeting was the FDA’s formation of an excipient working group to "help work on and resolve issues as well as to improve the type of information listed in the database."
IPEC America’s wants to encourage industry participation in this process and has invited excipient manufacturers that want to get involved to email questions and comments to Katherine Ulman of Dow Corning, IPEC Americas Vice-Chair for Science and Regulatory Policy